COMMUNIQUÉS West-GlobeNewswire

Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research
29/07/2026
Report discusses ProLectin-M Phase 2 clinical results, planned 408-patient registrational trial, the BXT-25 oxygen-therapeutic platform, and Bioxytran’s A-SUQAR commercial distribution agreement BOSTON, MASSACHUSETTS, [...]
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
29/07/2026
First BiTAC®-related patent applications filed in H1 2026 including patents covering composition of matter and proprietary payload platform, with additional patents secured in contributing technology areas including [...]
TRUE-See Systems Announces New Venture Funding
29/07/2026
TRUE-See’s AI-driven proprietary technology is designed to transform medical photography by making it accurate, reliable, versatile and easily accessible NEW ORLEANS, July 29, 2026 (GLOBE NEWSWIRE) -- TRUE-See Systems, [...]
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
29/07/2026
Successful initiation of the Phase 2/3 clinical trial of SIL204 at Tel Aviv Sourasky Medical Center (“TASMC” or “Ichilov”), one of Israel’s largest and most prominent academic medical centers, clears the site to [...]
Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
29/07/2026
Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA ’s U.S. Market Share [...]
Fortrea Reports Second Quarter 2026 Results
29/07/2026
Four consecutive quarters of execution to drive commercial, operational and financial excellence Increases full-year guidance Highlights For the three months ended June 30, 2026: Revenues of $678.2 million Book-to-bill [...]
Atavistik Bio Appoints Habib Dable to its Board of Directors
29/07/2026
Mr. Dable brings deep expertise in clinical development, commercialization, and corporate strategy to support Atavistik Bio’s next phase of growth CAMBRIDGE, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Atavistik Bio, a [...]
Biodexa lance des activités de soutien aux patients atteints de polypose adénomateuse familiale (PAF) et aux centres de traitement en France
29/07/2026
28 juillet 2026 Biodexa lance des activités de soutien aux patients atteints de polypose adénomateuse familiale (PAF) et aux centres de traitement en France Biodexa Pharmaceuticals PLC (NASDAQ : BDRX), une société [...]
Shape Therapeutics Receives Research Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance SHP-201, a One-Time Gene Therapy to Treat Parkinson’s Disease
29/07/2026
Grant supports IND-enabling studies of an intravenously delivered, disease-modifying gene therapy designed to reduce alpha-synuclein in the brain regions most affected by Parkinson’s disease SEATTLE, July 29, 2026 ( [...]
Integra LifeSciences Reports Second Quarter 2026 Financial Results
29/07/2026
PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending [...]
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
29/07/2026
Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations 90% of patients had no [60%] or mild [30%] cough ~450 total inhalations administered in patients with IPF [...]
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
29/07/2026
Actively enrolling patients across the US with anticipated topline data readout mid-2028 WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company [...]
Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy
29/07/2026
Q2 2026 revenues of $4.1 billion decreased by 1% in U.S. dollars year-over-year (YoY) and by 3% in local currency (LC) terms, mainly due to lower generics revenues. Our key innovative brands collectively grew 43% YoY in [...]
TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update
29/07/2026
Conference Call to be Held Monday, August 3, 2026, at 8:30 am ET NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 3, [...]
BrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026
29/07/2026
BURLINGTON, Mass. and JERUSALEM, July 29, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today [...]
Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
29/07/2026
WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Tasrif Pharmaceutical Announces Grant of Second U.S. Patent for Humanized Monoclonal Antibodies Against the Poliovirus Receptor (CD155)
29/07/2026
TSRF-786C demonstrates sub-nanomolar affinity, a favorable in vitro safety and immunogenicity profile, and broad potential across ADCs, bispecifics, and cell therapies NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Tasrif [...]
XORTX Appoints New Director
29/07/2026
CALGARY, Alberta, July 29, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing [...]
Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution
29/07/2026
FDA submission seeks to bring KHINDIVI to larger pediatric patient population within the adrenal insufficiency market New formulation successfully demonstrated bioequivalence to ALKINDI SPRINKLE ® Submission allows for [...]

Pages